Bristol-Myers Squibb (BMY) Poised for Upside With Registrational Data Ahead

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 on January 13, maintaining an Outperform rating on the company’s shares. The firm cited substantial pipeline flexibility in 2026 as the key justification for the higher target. Pixabay/Public Domain Leerink decreased its fourth-quarter 2025 earnings per share forecast by 29%, from $1.65 to $1.19, citing exp ...